| 8.003 0.223 (2.87%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.29 | 1-year : | 12.01 |
| Resists | First : | 8.81 | Second : | 10.29 |
| Pivot price | 7.43  |
|||
| Supports | First : | 7.29 | Second : | 6.36 |
| MAs | MA(5) : | 8.07 |
MA(20) : | 7.27 |
| MA(100) : | 7.7 |
MA(250) : | 7.48  |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 62.9 |
D(3) : | 74.4 |
| RSI | RSI(14): 60 |
|||
| 52-week | High : | 10.64 | Low : | 5.01 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NVAX ] has closed below upper band by 24.4%. Bollinger Bands are 46.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.33 - 8.38 | 8.38 - 8.42 |
| Low: | 7.64 - 7.68 | 7.68 - 7.72 |
| Close: | 7.94 - 8 | 8 - 8.07 |
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Mon, 19 Jan 2026
The Truth About Novavax Inc (NVAX): Comeback Season or Total Trap? - AD HOC NEWS
Thu, 15 Jan 2026
Improved Revenues Required Before Novavax, Inc. (NASDAQ:NVAX) Stock's 32% Jump Looks Justified - Sahm
Wed, 14 Jan 2026
Novavax (NVAX) Moves 11.9% Higher: Will This Strength Last? - Yahoo Finance
Wed, 14 Jan 2026
Improved Revenues Required Before Novavax, Inc. (NASDAQ:NVAX) Stock's 32% Jump Looks Justified - simplywall.st
Tue, 13 Jan 2026
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Tue, 13 Jan 2026
Novavax, Inc. (NVAX) Stock Analysis: Exploring a 64.87% Potential Upside Amid Volatile Biotech Landscape - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 163 (M) |
| Shares Float | 135 (M) |
| Held by Insiders | 8.7 (%) |
| Held by Institutions | 61.6 (%) |
| Shares Short | 52,590 (K) |
| Shares Short P.Month | 50,680 (K) |
| EPS | 2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.96 |
| Profit Margin | 32 % |
| Operating Margin | -112.7 % |
| Return on Assets (ttm) | 18 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -16.7 % |
| Gross Profit (p.s.) | 3.89 |
| Sales Per Share | 6.52 |
| EBITDA (p.s.) | 2.78 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -378 (M) |
| Levered Free Cash Flow | -455 (M) |
| PE Ratio | 3.98 |
| PEG Ratio | 0 |
| Price to Book value | -8.34 |
| Price to Sales | 1.22 |
| Price to Cash Flow | -3.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|